Cannabinoid CBG reduces anxiety and stress in first human clinical trial
A lesser-known cannabinoid that is gaining in popularity Cannabigerol (CBG) effectively reduced anxiety in a clinical trial without the intoxication typically associated with whole plant cannabis. It may even have some memory enhancing effects, according to a new study. For the study, researchers conducted the first human clinical trial investigating the acute effects of CBG on anxiety, stress and mood. The research revealed that 20 mg of hemp-derived CBG significantly reduced feelings of anxiety at 20, 45 and 60 minutes after ingestion compared to a placebo.
Li Wei is a Chinese-Canadian neuroscientist in Vancouver, studying brain plasticity and lifelong learning. He contributes articles on harnessing neurotechnology to expand human capabilities, drawing from his experiences in cross-cultural innovation hubs.